BRPI0815726A2 - terapia de combinação para câncer pancreático utilizando um peptídeo antigênico e agente quimioterápico - Google Patents

terapia de combinação para câncer pancreático utilizando um peptídeo antigênico e agente quimioterápico

Info

Publication number
BRPI0815726A2
BRPI0815726A2 BRPI0815726A BRPI0815726A BRPI0815726A2 BR PI0815726 A2 BRPI0815726 A2 BR PI0815726A2 BR PI0815726 A BRPI0815726 A BR PI0815726A BR PI0815726 A BRPI0815726 A BR PI0815726A BR PI0815726 A2 BRPI0815726 A2 BR PI0815726A2
Authority
BR
Brazil
Prior art keywords
pancreatic cancer
combination therapy
chemotherapeutic agent
antigenic peptide
cancer combination
Prior art date
Application number
BRPI0815726A
Other languages
English (en)
Portuguese (pt)
Inventor
Hiroki Yamaue
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BRPI0815726A2 publication Critical patent/BRPI0815726A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BRPI0815726A 2007-08-24 2008-08-19 terapia de combinação para câncer pancreático utilizando um peptídeo antigênico e agente quimioterápico BRPI0815726A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95792307P 2007-08-24 2007-08-24
PCT/JP2008/002232 WO2009028150A1 (en) 2007-08-24 2008-08-19 Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent

Publications (1)

Publication Number Publication Date
BRPI0815726A2 true BRPI0815726A2 (pt) 2016-01-05

Family

ID=40386893

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815726A BRPI0815726A2 (pt) 2007-08-24 2008-08-19 terapia de combinação para câncer pancreático utilizando um peptídeo antigênico e agente quimioterápico

Country Status (19)

Country Link
US (1) US8703713B2 (enExample)
EP (1) EP2195003A4 (enExample)
JP (1) JP5417667B2 (enExample)
KR (1) KR20100047899A (enExample)
CN (1) CN101883577A (enExample)
AR (1) AR068020A1 (enExample)
AU (1) AU2008292966C1 (enExample)
BR (1) BRPI0815726A2 (enExample)
CA (1) CA2697501A1 (enExample)
IL (1) IL204143A (enExample)
MX (1) MX2010002178A (enExample)
MY (1) MY160406A (enExample)
NZ (1) NZ583578A (enExample)
RU (1) RU2472522C2 (enExample)
SG (1) SG183770A1 (enExample)
TW (1) TWI436775B (enExample)
UA (1) UA100702C2 (enExample)
WO (1) WO2009028150A1 (enExample)
ZA (1) ZA201001580B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2375299T3 (es) 2002-09-12 2012-02-28 Oncotherapy Science, Inc. Péptidos kdr y vacunas que los contienen.
US20080034017A1 (en) * 2006-08-04 2008-02-07 Dominic Giampaolo Links to a common item in a data structure
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
JP5904552B2 (ja) * 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター 膵癌治療剤
DE102013214023B4 (de) * 2013-07-17 2015-02-12 Siemens Aktiengesellschaft Verfahren zu einem Auswerten und Vergleichen von zeitlich aufeinander folgenden kombinierten medizinischen Bildgebungsuntersuchungen sowie ein medizinisches Bildgebungssystem, das zu einem Ausführen des erfindungsgemäßen Verfahrens ausgelegt ist
JP6161098B2 (ja) * 2014-10-09 2017-07-12 国立大学法人山口大学 Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
CA2964361A1 (en) * 2014-10-14 2016-04-21 The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Peptide-based methods for treating pancreatic cancer
US20200147194A1 (en) * 2017-05-19 2020-05-14 Keio University Peptide vaccine and peptide vaccine composition for cranial nerve disease
US10413584B1 (en) 2018-08-29 2019-09-17 Riptide Bioscience, Inc. Peptides having immunomodulatory properties
US10548944B1 (en) 2018-10-19 2020-02-04 Riptide Bioscience, Inc. Antimicrobial peptides and methods of using the same
CN114959031A (zh) * 2022-05-20 2022-08-30 上海交通大学医学院附属瑞金医院 胰腺腺癌预后评估的标志物组合及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB213645A (en) 1922-12-22 1924-03-24 Frank Lincoln Morse Improvements in and relating to chain and sprocket wheel gearing
US3265572A (en) * 1961-09-20 1966-08-09 S B Penick And Company Process for preparing tyrociding and product produced thereby
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ES2230542T3 (es) * 1993-03-25 2005-05-01 MERCK & CO., INC. Inhibidor del factor de crecimiento celular endotelial vascular.
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998031794A1 (fr) 1997-01-17 1998-07-23 Toa Gosei Co., Ltd. Polypeptide liant le facteur vegf
AU2299099A (en) 1998-02-04 1999-08-23 Kyowa Hakko Kogyo Co. Ltd. Antibodies against human vegf receptor kdr
GB9804121D0 (en) 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
EP1086705A4 (en) 1998-05-20 2002-02-06 Kyowa Hakko Kogyo Kk INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ACTIVITY
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
ES2375299T3 (es) * 2002-09-12 2012-02-28 Oncotherapy Science, Inc. Péptidos kdr y vacunas que los contienen.
EP1567169A4 (en) 2002-11-04 2009-10-21 Xenoport Inc GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
DE602005027673D1 (de) * 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
EP1755608A1 (en) * 2004-06-03 2007-02-28 F.Hoffmann-La Roche Ag Treatment with gemcitabine and an egfr-inhibitor
EP1831237B1 (en) 2004-12-17 2008-08-20 Eli Lilly And Company Amide prodrug of gemcitabine, compositions and use thereof
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
CN101678065A (zh) 2007-02-16 2010-03-24 肿瘤疗法科学股份有限公司 脉络膜血管新生的疫苗疗法

Also Published As

Publication number Publication date
AR068020A1 (es) 2009-10-28
MX2010002178A (es) 2010-03-18
IL204143A (en) 2013-04-30
US8703713B2 (en) 2014-04-22
EP2195003A4 (en) 2011-07-06
AU2008292966B2 (en) 2012-07-19
TWI436775B (zh) 2014-05-11
SG183770A1 (en) 2012-09-27
TW200914037A (en) 2009-04-01
RU2010111139A (ru) 2011-09-27
US20110082088A1 (en) 2011-04-07
AU2008292966C1 (en) 2013-03-14
WO2009028150A1 (en) 2009-03-05
ZA201001580B (en) 2011-02-23
JP5417667B2 (ja) 2014-02-19
KR20100047899A (ko) 2010-05-10
RU2472522C2 (ru) 2013-01-20
CN101883577A (zh) 2010-11-10
MY160406A (en) 2017-03-15
CA2697501A1 (en) 2009-03-05
EP2195003A1 (en) 2010-06-16
JP2010536714A (ja) 2010-12-02
NZ583578A (en) 2012-07-27
UA100702C2 (ru) 2013-01-25
AU2008292966A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
BRPI0815726A2 (pt) terapia de combinação para câncer pancreático utilizando um peptídeo antigênico e agente quimioterápico
BRPI0818673A2 (pt) terapia de combinação de um anticorpo anti-cd20 tipo ii com um agente ativo anti-bcl-2
BRPI0722053A2 (pt) método para o tratamento de câncer, formulação anticâncer, método de uso da formulação, e, uso de metoxiamina
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BRPI0817293A2 (pt) Derivado de benzoquinona e3330 em combinação com agentes quimioterapêuticos para o tratamento de câncer e angiogenese
PT2186889E (pt) Péptido cdca1 e agente farmacêutico que o compreende
BRPI0814140A2 (pt) composição de peptídeos associados a tumor e vacina anticâncer relacionada
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0819361A2 (pt) Composição de tratamento de cabelos e agente de tratamento
BRPI0720546A2 (pt) Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto
BRPI0906576A2 (pt) Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
BR112012018951A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
BRPI0807544A2 (pt) Sólido farmacêutico e dose de vacina
HUE037082T2 (hu) Új lipidek és készítmények terápiás hatóanyagok szállítására
BRPI0818320A2 (pt) composição para tratamento de câncer de próstata (pca)
BRPI0717389A2 (pt) Dispositivos e métodos para avanço de stent
BRPI0914192A2 (pt) distribuição transdérmica de fármaco usando um osmólito e agente vasoativo
BRPI0815577A2 (pt) Peptídeo foxm1 e agente medicinal compreendendo o mesmo.
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
EP2025347A4 (en) PROPHYLACTIC AND THERAPEUTIC AGENTS AGAINST CANCER
BRPI0919236A2 (pt) terapêutica e vacinas de combinação de gas
BRPI0816236A2 (pt) Peptídeo cdh3 e agente medicinal contendo o mesmo
DK2063881T3 (da) Sammensætning og fremgangsmåde til virksom og sikker administration af halopyruvat til behandlingen af cancer
EP2123266A4 (en) THERAPEUTIC CANCER AND ANTI-CARCINOGENIC AGENT

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.